Press release
October 15, 2021
4 mins

Owkin named MedTech Visionaries, Best Oncology AI Company for Precision Medicine

Owkin, a French-American startup that uses artificial intelligence and Federated Learning for medical research, has been named the most disruptive company using AI to optimize and discover new cancer treatments at the MedTech Visionaries Awards.

Receiving the award for Best MedTech Company in the Field of Oncology AI for Precision Medicine, Owkin co-founder and clinical research doctor Thomas Clozel MD said that the award reflects how “speed and collaboration” have never been more important in medical research.

“Artificial intelligence is revolutionising how we diagnose and treat some of the most complex and intractable diseases. At Owkin, we use AI and Federated Learning technologies to get the upper hand in our millennia-old battle against cancer. By leaving patient data on-site, we enable researchers to collaborate at unprecedented speed while retaining data privacy – a crucial yet until now insurmountable obstacle to rapid, effective research”, said Thomas.

Owkin was co-founded by Thomas and Gilles Wainrib PhD, an academic pioneer in the field of artificial intelligence in biology, in 2016. The company’s mission is to connect the global healthcare industry through the safe and responsible use of data and the application of artificial intelligence for faster and more effective research and drug development.

Using Federated Learning, an advanced form of AI that preserves data and patient privacy by leaving all data on-site in hospitals and research centres, Owkin enables partners to unlock siloed datasets while protecting patient privacy and securing proprietary data. This allows partners to access unprecedented collaboration to improve patient outcomes.

The second annual MedTech Visionaries Awards showcase the most disruptive and innovative companies using technology to improve the way patients are treated. Hosted by the creative strategists Light4Soul and sponsored by Boost Awards. The MVA’s judges selected Owkin as the 2021 winner of the Best MedTech Company in the Field of Oncology AI for Precision Medicine.

Visit Owkin’s virtual booth at to learn more.

About Light4Soul

Light4Soul has been the go-to name for developing, hosting and maintaining websites for more than two decades. Internationally respected and recognized for design and brand awareness projects we work with your team or for your sole proprietorship to exceed your goals on time and on budget.

For more information, please visit and follow @OWKINscience on Twitter.

About Owkin

Owkin is the first full-stack TechBio company on a mission to understand complex biology and derive new multimodal biomarkers through AI.

We identify precision therapeutics, de-risk and accelerate clinical trials and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular, immunity and inflammation.

Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research across seven cancer indications.

Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like Fidelity, GV and Bpifrance, among others.